相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
2-8°C
- 保质期:
根据瓶身LOT号查询
- 英文名:
Collagenase D
- 库存:
有现货
- 供应商:
浙江羽翔生物科技有限公司
- CAS号:
见瓶身
- 规格:
5MG
属性
生物来源
Clostridium histolyticum
质量水平
100
无菌性
non-sterile
表单
lyophilized
collagenase activity
>0.15 U/mg lyophilizate
包装
pkg of 100 mg (11088858001)
pkg of 2.5 g (11088882001)
pkg of 500 mg (11088866001)
制造商/商品名称
Roche
浓度
(working concentration: 0.5 - 2.5 mg/ml)
技术
tissue processing: suitable
颜色
light brown
最佳pH
6.0-8.0
溶解性
water: soluble
NCBI登记号
WP_171012037
应用
cell analysis
异质活性
Clostripain 0.060 U/mg
Proteases 8 U/mg ( Azocoll)
Trypsin <0.2 U/mg (with BAEE)
储存温度
2-8°C
一般描述
应用
梭菌胶原酶已用于从多种类型的组织中进行细胞的制备,如肝细胞、脂肪细胞、胰岛、上皮细胞、肌肉细胞、内皮细胞等。然而,应根据经验确定每个批次的酶对破坏特定组织的适用性。
生化/生理作用
特点和优势
冻干粉,未灭菌
外形
制备说明
工作浓度:0.5 - 2.5mg/ml
储存条件(工作溶液):-15至-25°C
Roche建议仅重悬需要立即使用的冻干粉的量。重新配制的溶液可以在-15至-25℃下储存长达一周。因为重新配制后活性降低了,所以要避免反复冻融。
抑制剂:
胶原酶抑制剂:EDTA, EGTA, Cys, His, DTT, 2-巯基乙chun
胶原酶不会被血清所抑制。
梭菌蛋白酶抑制剂:TLCK
胰蛋白酶抑制剂:抑肽酶,胰蛋白酶抑制剂(蛋清,大豆)
酶活:
胶原酶活性:>0.15 U/mg (基于Wünsch) (+25°C, 4-苯基-偶氮苄基-氧基羰基-Pro-Leu-Gly-Pro-D-Arg作为底物)
污染性酶活:胰蛋白酶,梭菌蛋白酶和总蛋白水解活性
胶原酶D具有正常至高的胶原酶活性,以及非常低的胰蛋白酶活性(通常<0.2单位/mg,BAEE作为底物)。
其他说明
通常,胶原酶活性是以Mandl单位(在+37℃下5小时内从胶原释放的1 μmol亮氨酸)给出的。
不幸的是,两个活性单位之间没有统一的转换因子,因为Mandl单位部分取决于胶原酶制剂中污染性蛋白酶的浓度,而这是一个不确定的变量。较纯的胶原酶制剂相对于粗制剂在Mandl单位中实际上具有更低的比活性。梭菌制剂通常具有约1:1800的转换因子(如某个特定批次的梭菌胶原酶所含有的约0.15 Wünsch U/mg和250 Mandl U/mg)。
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Endothelial AMPKα1/PRKAA1 exacerbates inflammation in HFD-fed mice.
Excess nutrient-induced endothelial cell inflammation is a hallmark of high fat diet (HFD)-induced metabolic syndrome. Pharmacological activation of the protein kinase AMP-activated α1 (PRKAA1) also known as AMPKα1, shows its beneficial effects in many studies of cardiometabolic disorders. However, AMPKα1, as a major cellular sensor of energy and nutrients in endothelial cells, has not been studied for its physiological role in excess nutrient-induced endothelial cell (EC) inflammation. Wild-type and EC-specific Prkaa1 knockout mice were fed with an HFD. Body weight, fat mass composition, glucose, and lipid levels were monitored regularly. Insulin sensitivity was analysed systemically and in major metabolic organs/tissues. Inflammation status in metabolic organs/tissues were examined with quantitative RT-PCR and flow cytometry. Additionally, metabolic status, inflammation severity, and signalling in cultured ECs were assayed with multiple approaches at the molecular level. EC Prkaa1 deficiency unexpectedly alleviated HFD-induced metabolic syndromes including decreased body weight and fat mass, enhanced glucose clearance and insulin sensitivity, and relieved adipose inflammation and hepatic steatosis. Mechanistically, PRKAA1 knockdown in cultured ECs reduced endothelial glycolysis and fatty acid oxidation, decreased levels of acetyl-CoA and suppressed transcription of inflammatory molecules mediated by ATP citrate lyase and histone acetyltransferase p300. This unexpected pro-inflammatory effect of endothelial AMPKα1/PRKAA1 in a metabolic context provides additional insight in AMPKα1/PRKAA1 activities. An in-depth study and thoughtful consideration should be applied when AMPKα1/PRKAA1 is used as a therapeutic target in the treatment of metabolic syndrome.
技术资料暂无技术资料 索取技术资料





![SIGMA B1760-100MG 苯并[a]芘 50-32-8](https://img1.dxycdn.com/p/s14/2025/0224/350/8045074956224883981.jpg!wh200)



